"company","name","title","link"
"Intellia Therapeutics","Intellia Therapeutics","fDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics","https://ir.intelliatx.com/news-releases/news-release-details/fda-accepts-investigational-new-drug-application-crisprcas9"
"Beam Therapeutics","Beam Therapeutics","Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results","https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-reports-business-updates-and-full-year-2019"
"Bluebird Bio","Bluebird Bio","Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA","http://investor.bluebirdbio.com/news-releases/news-release-details/bristol-myers-squibb-and-bluebird-bio-announce-submission"
"Bluebird Bio","Bluebird Bio","bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development","http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-provides-assessment-impact-covid-19-update-business"
"Harpoon Therapeutics","Harpoon Therapeutics","Harpoon Therapeutics Appoints Two New Members to Its Board of Directors","https://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-appoints-two-new-members-its-board"
"Cabaletta Therapeutics","Cabaletta Therapeutics","Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update","https://investors.cabalettabio.com/news-releases/news-release-details/cabaletta-bio-reports-fourth-quarter-and-full-year-2019"
"TCR2 Therapeutics","TCR2 Therapeutics","TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors","http://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-announces-immuno-oncology-pioneer-dr-axel-hoos"
"TCR2 Therapeutics","TCR2 Therapeutics","TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day","http://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-present-goldman-sachs-cell-therapy-day"
"TCR2 Therapeutics","TCR2 Therapeutics","TCR² Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update","http://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-reports-fourth-quarter-and-full-year-2019"
"AgeX Therapeutics","AgeX Therapeutics","","https://investors.agexinc.com/news/news-details/2020/AgeX-Therapeutics-Reports-Fourth-Quarter-and-Annual-2019-Financial-Results-and-Provides-Business-Update/default.aspx"
"AgeX Therapeutics","AgeX Therapeutics","","https://investors.agexinc.com/news/news-details/2020/AgeX-Therapeutics-Licensee-ImStem-Biotechnology-Announces-FDA-has-Lifted-the-Hold-and-Cleared-the-Investigational-New-Drug-Application-for-IMS001-for-the-Treatment-of-Multiple-Sclerosis/default.aspx"
"Moderna","Moderna","Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus","https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-award-us-government-agency-barda-483-million"
"Moderna","Moderna","Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day","https://investors.modernatx.com/news-releases/news-release-details/moderna-highlights-opportunity-mrna-vaccines-its-first-vaccines"
"Moderna","Moderna","Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format","https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-its-2020-annual-meeting-stockholders-will-be"
"Moderna","Moderna","Moderna to Present at 19th Annual Needham Healthcare Conference","https://investors.modernatx.com/news-releases/news-release-details/moderna-present-19th-annual-needham-healthcare-conference"
"Moderna","Moderna","Moderna to Host Virtual Vaccines Day on April 14, 2020","https://investors.modernatx.com/news-releases/news-release-details/moderna-host-virtual-vaccines-day-april-14-2020"
"Moderna","Moderna","Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development","https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-update-impact-covid-19-business-operations-and"
"Moderna","Moderna","Moderna to Present at MIT Lecture Series","https://investors.modernatx.com/news-releases/news-release-details/moderna-present-mit-lecture-series"
"Vir Bio","Vir Bio","VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial","https://investors.vir.bio/news-releases/news-release-details/vir-2218-demonstrates-dose-dependent-and-durable-reductions"
"Vir Bio","Vir Bio","Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment","https://investors.vir.bio/news-releases/news-release-details/samsung-biologics-and-vir-biotechnology-enter-agreement-large"
"Vir Bio","Vir Bio","Vir Biotechnology to Host Key Opinion Leader Call and Present Update on  Phase 1/2 HBV Clinical Trial with siRNA VIR-2218","https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-host-key-opinion-leader-call-and-present"
"Vir Bio","Vir Bio","GSK and Vir Biotechnology enter collaboration to find coronavirus solutions","https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus"
"Vir Bio","Vir Bio","Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19","https://investors.vir.bio/news-releases/news-release-details/vir-and-alnylam-expand-collaboration-advance-investigational"
"Vir Bio","Vir Bio","Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19","https://investors.vir.bio/news-releases/news-release-details/generation-bio-and-vir-biotechnology-collaborate-research"
"Vir Bio","Vir Bio","Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results","https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-provides-corporate-update-and-reports-fourth"
"Vir Bio","Vir Bio","Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19","https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-proceeding-two-clinical-development-candidates"
"Blueprint Medicines","Blueprint Medicines","Blueprint Medicines Announces the Achievement of Key Portfolio Milestones","http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-achievement-key-portfolio"
"Ideaya Biosciences","Ideaya Biosciences","IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update","https://ir.ideayabio.com/news-releases/news-release-details/ideaya-biosciences-inc-reports-fourth-quarter-2019-financial"
"Ideaya Biosciences","Ideaya Biosciences","IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update","https://ir.ideayabio.com/news-releases/news-release-details/ideaya-biosciences-announces-ide196-monotherapy-phase-2-dose"
"Ideaya Biosciences","Ideaya Biosciences","IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations","https://ir.ideayabio.com/news-releases/news-release-details/ideaya-and-pfizer-enter-clinical-trial-collaboration-and-supply"